Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946685 | 0.87 | CYP19A1 (0.64) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL13821868 | 0.80 | CYP19A1 (0.59) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL95170 | 0.77 | CYP19A1 (0.78) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL13403830 | 0.77 | CYP19A1 (0.52) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL324969 | 0.76 | CA2 (0.46) | TSHR | |
| SCHEMBL9913645 | 0.74 | CYP19A1 (0.37) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL9913659 | 0.74 | CYP2A6 (0.39) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL9913657 | 0.74 | CA2 (0.39) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL9913656 | 0.74 | GSK3B (0.38) | CYP19A1CYP3A4CYP11B1TSHRCYP11B2 | |
| SCHEMBL8773276 | 0.70 | MMP3 (0.52) | TSHRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150524-B2 | Pure intermediate | GENERICS [UK] LIMITED (GB) | 2015-10-06 | — | — | US | disclosed |
| US-20130203826-A1 | Pure Intermediate | GENERICS [UK] LIMITED (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8198460-B2 | Process for preparation of letrozole and its intermediates | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2012-06-12 | — | — | US | disclosed |
| US-8003804-B2 | Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile intermediate | CIPLA LIMITED (IN) | 2011-08-23 | — | — | US | disclosed |
| US-20100234617-A1 | PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2010-09-16 | — | — | US | disclosed |
| US-20100190997-A1 | Process for the Preparation of Letrozole | CADILA HEALTHCARE LIMITED (IN) | 2010-07-29 | — | — | US | disclosed |
| US-7705159-B2 | Process for the preparation of letrozole | SICOR, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090270633-A1 | Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile intermediate | CIPLA LIMITED (IN) | 2009-10-29 | — | — | US | disclosed |
| US-7465749-B2 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CHEMAGIS, LTD. (IL) | 2008-12-16 | — | — | US | disclosed |
| US-7459565-B2 | Regiospecific process for the preparation of 4-[1- (4-cyanophenyl)-1-(1,2,4-triazol-1-yl)methyl] benzonitrile | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2008-12-02 | — | — | US | disclosed |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CHEMAGIS LTD. (IL) | 2007-05-17 | — | — | US | disclosed |
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | DR. REDDY'S LABORATORIES, INC. | 2007-05-03 | — | — | US | disclosed |
| US-20070066831-A1 | Process for the preparation of letrozole | SICOR, INC. | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100149-A1 | PROCESS FOR PREPARING LETROZOLE | CYP19A1, CYP2C19, CYP17A1 | CYP19A1 1/4885CYP3A4 4/4885CYP11B1 80/4885 |
| US-20070066831-A1 | Process for the preparation of letrozole | CYP19A1, CYP4B1, CYP3A4 | CYP19A1 1/4885CYP3A4 3/4885CYP11B1 14/4885 |
| US-20070112203-A1 | The impurity isoletrozole is more rapidly oxidized to 4,4'-dicyanobenzophenone than Letrozole, which can be seperated by crystallization to yield highly purified letrozole | CYP19A1, HSD17B11, SHBG | CYP19A1 1/4885CYP3A4 6/4885CYP11B1 27/4885 |
| US-20130203826-A1 | Pure Intermediate | CYP19A1, CYP11A1, CYP11B1 | CYP19A1 1/4885CYP3A4 9/4885CYP11B1 3/4885 |
| US-20090270633-A1 | Synthesis of 4-[1-(4-cyano phenyl)-(1,2,4-triazol-1-yl)methyl] benzonitrile and 4-[1-(1H-1,2,4-triazol-1-yl)methylene benzonitrile intermediate | CYP19A1, CDK14, KISS1R | CYP19A1 1/4885CYP3A4 10/4885CYP11B1 77/4885 |
| US-20100234617-A1 | PROCESS FOR PREPARATION OF LETROZOLE AND ITS INTERMEDIATES | CYP19A1, CYP4B1, CYP3A4 | CYP19A1 1/4885CYP3A4 3/4885CYP11B1 9/4885 |
| US-20100190997-A1 | Process for the Preparation of Letrozole | CYP19A1, CYP11A1, HSD17B11 | CYP19A1 1/4885CYP3A4 6/4885CYP11B1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.